Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations
- PMID: 10052756
- DOI: 10.1089/088922299311439
Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations
Abstract
The effect of aggressive antiretroviral therapy on spontaneous apoptosis (AP) in CD4+ and CD8+ lymphocytes expressing CD45RO (memory cells) and CD45RA (naive cells) and their relationship to cellular activation and viral load were examined. Ten patients receiving simultaneous treatment with d4T, ddI, and HU were evaluated. Flow cytometric analysis showed significant levels of AP (measured by TUNEL assay) among memory and naive T cells and an enhanced expression of CD38 and HLA-DR activation markers. The percentage of apoptotic CD4+CD45RO+ and CD4+CD45RA+ cells decreased, respectively, from 34 +/- 3.3 and 29 +/- 3.6 prior to treatment to 20.5 +/- 4 and 22 +/- 3.8 at week 8 into therapy. The percentage of apoptotic CD8+CD45RO+ and CD8+CD45RA+ cells similarly decreased, respectively, from 20 +/- 2.5 and 24 +/- 3 prior to treatment to 14.5 +/- 2.7 and 16 +/- 3 at week 8 into treatment. The percentage of CD4+ cells expressing the activation markers CD38 and HLA-DR decreased from 27 +/- 6 to 13 +/- 2 and from 26 +/- 4 to 13.5 +/- 3, respectively. The percentage of CD8+ cells expressing either CD38 or HLA-DR fell from 22 +/- 3 to 10 +/- 2 for the former and from 39 +/- 5 to 22 +/- 4 for the latter. This was associated with a significant decrease in viral load (mean, 1.4 log10), and a decline in circulating plasma TNF-alpha and sIL-2R levels from 50.5 +/- 10 to 21 +/- 6 and 92.5 +/- 11 to 68 +/- 9, respectively. These data indicate that short-term therapy with ddI, d4T, and HU in combination diminished AP, immune activation, and partially restored naive and memory T cell subpopulations.
Similar articles
-
Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1869-75. doi: 10.1089/08892220050195829. AIDS Res Hum Retroviruses. 2000. PMID: 11118072 Clinical Trial.
-
Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.AIDS Res Hum Retroviruses. 1998 May 1;14(7):561-9. doi: 10.1089/aid.1998.14.561. AIDS Res Hum Retroviruses. 1998. PMID: 9591710
-
Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.AIDS. 2004 Jun 18;18(9):1251-61. doi: 10.1097/00002030-200406180-00003. AIDS. 2004. PMID: 15362657
-
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.Sex Transm Infect. 1999 Aug;75(4):218-24. doi: 10.1136/sti.75.4.218. Sex Transm Infect. 1999. PMID: 10615305 Free PMC article. Review.
-
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.AIDS. 1998 Sep 10;12(13):1567-70. doi: 10.1097/00002030-199813000-00002. AIDS. 1998. PMID: 9764774 Review. No abstract available.
Cited by
-
Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load.AIDS. 2002 Nov 8;16(16):2119-27. doi: 10.1097/00002030-200211080-00003. AIDS. 2002. PMID: 12409732 Free PMC article.
-
Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients.Clin Exp Immunol. 2000 Apr;120(1):101-6. doi: 10.1046/j.1365-2249.2000.01187.x. Clin Exp Immunol. 2000. PMID: 10759770 Free PMC article. Clinical Trial.
-
Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.Clin Diagn Lab Immunol. 2001 Jul;8(4):671-7. doi: 10.1128/CDLI.8.4.671-677.2001. Clin Diagn Lab Immunol. 2001. PMID: 11427409 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials